Pseudomonas aeruginosa reduces VX-809 stimulated F508del-CFTR chloride secretion by airway epithelial cells

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Stanton, Bruce A ^a   Coutermarsh, Bonita ^a   Barnaby, Roxanna ^a   Hogan, Deborah ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; LUMACAFTOR; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPYRIDINE DERIVATIVE; CFTR PROTEIN, HUMAN; CHLORIDE; DNA BINDING PROTEIN; FEV PROTEIN, HUMAN; NUCLEAR PROTEIN;

ARTICLE; BACTERIUM ISOLATE; BIOTINYLATION; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIMARY CULTURE; PROTEIN SECRETION; PSEUDOMONAS AERUGINOSA; WESTERN BLOTTING; BRONCHUS; CELL LINE; CELL MEMBRANE; CYSTIC FIBROSIS; DRUG EFFECTS; METABOLISM; MICROBIOLOGY; MUTATION; PHYSIOLOGY; PSEUDOMONAS INFECTION; SECRETION (PROCESS);

AMINOPYRIDINES; BENZODIOXOLES; BRONCHI; CELL LINE; CELL MEMBRANE; CHLORIDES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA-BINDING PROTEINS; EPITHELIAL CELLS; HUMANS; MUTATION; NUCLEAR PROTEINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84953302717     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127742     Document Type: Article

References (31)

1. Guggino WB, Stanton BA. New insights into cystic fibrosis: molecular switches that regulate CFTR. Nature reviews Molecular cell biology. 2006; 7(6):426-36. doi: 10.1038/nrm1949 PMID: 16723978.
2. Riordan JR. CFTR function and prospects for therapy. Annual review of biochemistry. 2008; 77:701-26. doi: 10.1146/annurev.biochem.75.103004.142532 PMID: 18304008.
3. Wang Y, Wrennall JA, Cai Z, Li H, Sheppard DN. Understanding how cystic fibrosis mutations disrupt CFTR function: from single molecules to animal models. The international journal of biochemistry & cell biology. 2014; 52:47-57. doi: 10.1016/j.biocel.2014.04.001 PMID: 24727426.
4. Collawn JF, Matalon S. CFTR and lung homeostasis. American journal of physiology Lung cellular and molecular physiology. 2014; 307(12):L917-23. doi: 10.1152/ajplung.00326.2014 PMID: 25381027; PubMed Central PMCID: PMC4269691.
5. Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nature medicine. 2012; 18(4):509-19. doi: 10.1038/nm.2715 PMID: 22481418; PubMed Central PMCID: PMC3577071.
6. Ballok AE, O\'Toole GA. Pouring salt on a wound: Pseudomonas aeruginosa virulence factors alter Na+ and Cl- flux in the lung. Journal of bacteriology. 2013; 195(18):4013-9. doi: 10.1128/JB.00339-13 PMID: 23836869; PubMed Central PMCID: PMC3754746.
7. Jensen TJ, Loo MA, Pind S, Williams DB, Goldberg AL, Riordan JR. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell. 1995; 83(1):129-35. PMID: 7553864.
8. Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell. 1995; 83(1):121-7. PMID: 7553863.
9. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(44):18825-30. doi: 10.1073/pnas.0904709106 PMID: 19846789; PubMed Central PMCID: PMC2773991.
10. Haws CM, Nepomuceno IB, Krouse ME, Wakelee H, Law T, Xia Y, et al. Delta F508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines. The American journal of physiology. 1996; 270(5 Pt 1):C1544-55. PMID: 8967457.
11. Ramsey B, Boyle MP, Elborn J, Huang X, Marigowd G, al. e. Effect of Lumicaftor in combination with Ivacaftor in patients with Cystic fibrosis who are homozygous for F508del-CFTR: Transport study. Pediatric Pulmonology. 2014; 49:305.
12. Bomberger JM, Ye S, Maceachran DP, Koeppen K, Barnaby RL, O\'Toole GA, et al. A Pseudomonas aeruginosa toxin that hijacks the host ubiquitin proteolytic system. PLoS pathogens. 2011; 7(3): e1001325. doi: 10.1371/journal.ppat.1001325 PMID: 21455491; PubMed Central PMCID: PMC3063759.
13. Bomberger JM, Maceachran DP, Coutermarsh BA, Ye S, O\'Toole GA, Stanton BA. Long-distance delivery of bacterial virulence factors by Pseudomonas aeruginosa outer membrane vesicles. PLoS pathogens. 2009; 5(4):e1000382. doi: 10.1371/journal.ppat.1000382 PMID: 19360133; PubMed Central PMCID: PMC2661024.
14. MacEachran DP, Ye S, Bomberger JM, Hogan DA, Swiatecka-Urban A, Stanton BA, et al. The Pseudomonas aeruginosa secreted protein PA2934 decreases apical membrane expression of the cystic fibrosis transmembrane conductance regulator. Infection and immunity. 2007; 75(8):3902-12. doi: 10.1128/ IAI.00338-07 PMID: 17502391; PubMed Central PMCID: PMC1951978.
15. Fulcher ML, Randell SH. Human nasal and tracheo-bronchial respiratory epithelial cell culture. Methods in molecular biology. 2013; 945:109-21. doi: 10.1007/978-1-62703-125-7-8 PMID: 23097104.
16. Bomberger JM, Coutermarsh BA, Barnaby RL, Stanton BA. Arsenic promotes ubiquitinylation and lysosomal degradation of cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels in human airway epithelial cells. The Journal of biological chemistry. 2012; 287(21):17130-9. doi: 10. 1074/jbc.M111.338855 PMID: 22467879; PubMed Central PMCID: PMC3366821.
17. Talebian L, Coutermarsh B, Channon JY, Stanton BA. Corr4A and VRT325 do not reduce the inflammatory response to P. aeruginosa in human cystic fibrosis airway epithelial cells. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2009; 23(1-3):199-204. doi: 10.1159/000204108 PMID: 19255514; PubMed Central PMCID: PMC3711581.
18. Swiatecka-Urban A, Brown A, Moreau-Marquis S, Renuka J, Coutermarsh B, Barnaby R, et al. The short apical membrane half-life of rescued {Delta}F508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of {Delta}F508-CFTR in polarized human airway epithelial cells. The Journal of biological chemistry. 2005; 280(44):36762-72. doi: 10.1074/jbc. M508944200 PMID: 16131493.
19. Swiatecka-Urban A, Talebian L, Kanno E, Moreau-Marquis S, Coutermarsh B, Hansen K, et al. Myosin Vb is required for trafficking of the cystic fibrosis transmembrane conductance regulator in Rab11a-specific apical recycling endosomes in polarized human airway epithelial cells. The Journal of biological chemistry. 2007; 282(32):23725-36. doi: 10.1074/jbc.M608531200 PMID: 17462998.
20. Moreau-Marquis S, Coutermarsh B, Stanton BA. Combination of hypothiocyanite and lactoferrin (ALX-109) enhances the ability of tobramycin and aztreonam to eliminate Pseudomonas aeruginosa biofilms growing on cystic fibrosis airway epithelial cells. The Journal of antimicrobial chemotherapy. 2015; 70(1):160-6. doi: 10.1093/jac/dku357 PMID: 25213272; PubMed Central PMCID: PMC4267504.
21. Bomberger JM, Guggino WB, Stanton BA. Methods to monitor cell surface expression and endocytic trafficking of CFTR in polarized epithelial cells. Methods in molecular biology. 2011; 741:271-83. doi: 10.1007/978-1-61779-117-8-18 PMID: 21594791.
22. Veit G, Avramescu RG, Perdomo D, Phuan PW, Bagdany M, Apaja PM, et al. Some gating potentiators, including VX-770, diminish DeltaF508-CFTR functional expression. Science translational medicine. 2014; 6(246):246ra97. doi: 10.1126/scitranslmed.3008889 PMID: 25101887.
23. Cholon DM, Quinney NL, Fulcher ML, Esther CR Jr., Das J, Dokholyan NV, et al. Potentiator ivacaftor abrogates pharmacological correction of DeltaF508 CFTR in cystic fibrosis. Science translational medicine. 2014; 6(246):246ra96. doi: 10.1126/scitranslmed.3008680 PMID: 25101886; PubMed Central PMCID: PMC4272825.
24. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(46):18843-8. doi: 10. 1073/pnas.1105787108 PMID: 21976485; PubMed Central PMCID: PMC3219147.
25. Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. The Lancet Respiratory medicine. 2014; 2(7):527-38. doi: 10.1016/S2213-2600(14)70132-8 PMID: 24973281.
26. Bahl CD, Hvorecny KL, Bridges AA, Ballok AE, Bomberger JM, Cady KC, et al. Signature motifs identify an Acinetobacter Cif virulence factor with epoxide hydrolase activity. The Journal of biological chemistry. 2014; 289(11):7460-9. doi: 10.1074/jbc.M113.518092 PMID: 24474692; PubMed Central PMCID: PMC3953260.
27. Stanke F, van Barneveld A, Hedtfeld S, Wolfl S, Becker T, Tummler B. The CF-modifying gene EHF promotes p.Phe508del-CFTR residual function by altering protein glycosylation and trafficking in epithelial cells. European journal of human genetics: EJHG. 2014; 22(5):660-6. doi: 10.1038/ejhg.2013. 209 PMID: 24105369; PubMed Central PMCID: PMC3992571.
28. Stanke F, Hedtfeld S, Becker T, Tummler B. An association study on contrasting cystic fibrosis endophenotypes recognizes KRT8 but not KRT18 as a modifier of cystic fibrosis disease severity and CFTR mediated residual chloride secretion. BMC medical genetics. 2011; 12:62. doi: 10.1186/1471-2350-12-62 PMID: 21548936; PubMed Central PMCID: PMC3107781.
29. Guimbellot JS, Chaudhry IG, Cholon DM, Esther CR, et al. Influence of bacteria of F508del CFTR correction by VX-809. Pediatric Pulmonology. 2014; 49:217-8.
30. Machen TE. Innate immune response in CF airway epithelia: hyperinflammatory? American journal of physiology Cell physiology. 2006; 291(2):C218-30. doi: 10.1152/ajpcell.00605.2005 PMID: 16825601.
31. Moreau-Marquis S, Barnaby RL, Coutermarsh BA, Stanton BA. Pseudomonas aeruginosa reduces the ability of VX-809 to rescue F508del-CFTR chloride secretion and mucociliary transport by airway epithelial cells. Pediatric Pulmonology. 2013; 48:255-6.